Sign In
Buy MRK
$113.87
-1.62 (-1.40%)
At Close: Jun 18, 2026
2 Magnificent Stocks to Buy That Are Near 52-Week Lows
09:45am, Tuesday, 05'th Nov 2024
These stocks near 52-week lows could be ready to rebound.
Merck vs. Bristol-Myers: Analyst Views Differ After Q3 Earnings
07:01am, Tuesday, 05'th Nov 2024
With many of the Magnificent 7 stocks reporting earnings the week of October 28, investors' attention was on technology stocks. But that means you may have overlooked two biopharmaceutical companies t
Investing Groups Digest: Mag 7 In The Market Spotlight
12:00pm, Monday, 04'th Nov 2024
Seeking Alpha's Investing Group leaders presented their earnings assessments from Mag 7 tech giants. Are investors missing hidden opportunities with BDCs, CEFs, mREITs, and preferreds? The case is mad
Is It Time to Buy October's Worst-Performing Dow Jones Stocks?
02:37pm, Sunday, 03'rd Nov 2024
The Dow finished October down slightly. Should you buy any of these blue chips?
2 Dividend Stocks to Buy for a Lifetime of Passive Income
11:55am, Saturday, 02'nd Nov 2024
These are the kinds of stocks that can allow investors to sleep easy at night.
Buy 3 November Dogs Of The Dow And Watch 7 More
04:19am, Saturday, 02'nd Nov 2024
"The Dow® [adds a stock] if the company has an excellent reputation,
Merck's Gardasil Shot Challenges To Continue, Analysts Optimistic For Newly Approved Sotatercept For Rare Lung Disease
02:33pm, Friday, 01'st Nov 2024
On Thursday, Merck & Co Inc MRK reported third-quarter sales of $16.66 billion, up 4% year over year, beating the consensus of $16.47 billion.
Is Merck Stock a Buy?
07:15am, Friday, 01'st Nov 2024
The next few years might get bumpy for the pharmaceutical giant, but the longer term looks better.
Merck & Co., Inc. (MRK) Q3 2024 Earnings Conference Call Transcript
01:07pm, Thursday, 31'st Oct 2024
Start Time: 09:00 January 1, 0000 10:00 AM ET Merck & Co., Inc. (NYSE:MRK ) Q3 2024 Earnings Call October 31, 2024, 09:00 AM ET Company Participants Peter Dannenbaum - SVP, IR Rob Davis - Chairman and
Merck Q3 Earnings & Sales Top, Stock Down on Lowered '24 View
12:45pm, Thursday, 31'st Oct 2024
MRK posts better-than-expected third-quarter results. The company lowers its guidance, likely due to the soft sales performance of the Gardasil vaccines.
Merck (MRK) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
10:36am, Thursday, 31'st Oct 2024
While the top- and bottom-line numbers for Merck (MRK) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare
Merck (MRK) Q3 Earnings and Revenues Top Estimates
08:40am, Thursday, 31'st Oct 2024
Merck (MRK) came out with quarterly earnings of $1.57 per share, beating the Zacks Consensus Estimate of $1.50 per share. This compares to earnings of $2.13 per share a year ago.
Merck CEO Robert Davis on Q3 results: Our portfolio sets us up for a good finish to the year
07:53am, Thursday, 31'st Oct 2024
Merck CEO Robert Davis joins 'Squawk Box' to discuss the company's quarterly earnings results, which topped expectations as the company saw strong sales from its top-selling cancer drug Keytruda, rece
Merck tops estimates despite muted Gardasil and diabetes drug sales
07:41am, Thursday, 31'st Oct 2024
Merck & Co Inc (NYSE:MRK, ETR:6MK) has topped third-quarter estimates despite flagging sales of its Gardasil jab, diabetes drugs and Covid-19 treatment. Revenue for the three months to September climb
Merck tops earnings estimates on strong demand for Keytruda even as HPV vaccine sales fall
07:31am, Thursday, 31'st Oct 2024
CNBC's Becky Quick reports on the company's quarterly earnings results.
